Research Peptides Studied on the Growth Hormone Axis: An Overview
The growth hormone (GH) axis is one of the most heavily studied signalling systems in peptide research, and the compounds associated with it fall into a handful of clear categories. Rather than treating each peptide in isolation, this overview groups them by where they act - upstream at the pituitary, at the parallel ghrelin pathway, downstream at the tissue level, or as the hormone itself - so that their relationships become visible at a glance.
How the axis is organized
At the top of the axis, the hypothalamus releases GHRH to stimulate the pituitary and somatostatin to restrain it. The pituitary secretes GH in pulses; GH then acts on the liver and other tissues to raise insulin-like growth factor 1 (IGF-1), which mediates many of GH's downstream effects and also feeds back to keep the system in balance. Research peptides slot into this picture at four points, summarized in the table below.
| Category | Mechanism | Example compounds |
|---|---|---|
| GHRH analogs | Bind the GHRH receptor on pituitary somatotrophs to stimulate pulsatile GH release, feedback preserved | Sermorelin, tesamorelin, CJC-1295 |
| Ghrelin-receptor secretagogues | Activate GHS-R1a, the ghrelin receptor, as a parallel stimulatory route to GH release | Ipamorelin, GHRP-2, GHRP-6, hexarelin |
| Downstream IGF-1 family | Act below the pituitary at the growth-factor level rather than triggering a GH pulse | IGF-1 LR3, PEG-MGF |
| Recombinant growth hormone | Supplies the hormone itself rather than prompting its release | HGH 191aa somatropin |
GHRH analogs
GHRH analogs mimic growth-hormone-releasing hormone and act at the GHRH receptor. Sermorelin is the shortest-acting, corresponding to the native GHRH(1-29) fragment. Tesamorelin is a stabilized analog studied in visceral-fat and lipodystrophy research, and CJC-1295 carries substitutions that extend its active window and is frequently paired with a secretagogue. All three preserve the pituitary's own pulse timing and downstream feedback, which is the defining trait of the category.
Ghrelin-receptor secretagogues
This group activates the growth hormone secretagogue receptor, a separate stimulatory pathway from GHRH. Ipamorelin is a selective pentapeptide noted for minimal effect on cortisol and prolactin. GHRP-2 and GHRP-6 are peptide secretagogues from the growth-hormone-releasing peptide series, while hexarelin is a potent related agonist. Because these act on a different receptor from the GHRH analogs, the two classes are often studied together and their signals can be additive. The ipamorelin versus tesamorelin comparison works through this two-receptor contrast in detail.
Downstream IGF-1 family
Some research compounds act below the pituitary, at the level of the growth factors that GH normally induces. IGF-1 LR3 is a long-acting analog of insulin-like growth factor 1 with reduced binding to its carrier proteins, which extends its activity in models. PEG-MGF is a pegylated form of mechano-growth factor, a splice variant of IGF-1 studied for its role in local tissue signalling. These act downstream rather than triggering a GH pulse, so they occupy a different niche than the secretagogues even though they belong to the same axis.
Recombinant growth hormone
Finally, HGH 191aa somatropin is recombinant human growth hormone itself - the full 191-amino-acid protein - rather than a compound that prompts the pituitary to release its own. It supplies the hormone directly, which is the key conceptual difference from every secretagogue and GHRH analog above: it does not depend on, and can override, the native feedback of the axis. That property makes it a distinct reference point for research that compares direct hormone supply against stimulated release.
Half-life and stability across the axis
One reason the categories are worth separating is that stability varies widely across them. The native-style GHRH fragment sermorelin is short-acting and cleared within minutes, while stabilized analogs and pegylated growth factors are engineered to persist far longer. The ghrelin-receptor peptides sit toward the shorter end as well. Recombinant growth hormone behaves differently again as a full protein rather than a short signalling peptide. These differences feed directly into how each material is stored and how a study schedules its measurements, so the category a compound falls into is a practical guide as much as a mechanistic one.
Choosing between the categories in research
The practical value of grouping these compounds is that it clarifies what a given experiment is probing. Work aimed at the pituitary's own release machinery points toward GHRH analogs or secretagogues; work at the tissue or growth-factor level points toward the IGF-1 family; and work that needs the hormone supplied directly points to recombinant GH. Keeping the four categories separate also helps when reading storage and handling notes, since the peptides differ in stability and half-life across the groups. The full catalogue is available on the store.
Research use only. This article is educational and is not medical, legal, or financial advice. The compounds discussed are not approved for human or veterinary use, consumption, or therapeutic application.